Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin vs. Fluconazole in Invasive Candidiasis
NCT01176058Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anidulafungin in candidemia and invasive candidiasis (2 arms), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Global Response at End of Intravenous Treatment (EOIT). Started Dec 2010; status: terminated.
02
Drugs
anidulafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT01176058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01176058.